See the DrugPatentWatch profile for Roflumilast
Roflumilast is the generic name for the prescription medication Daliresp [1]. Daliresp is used to treat chronic obstructive pulmonary disease (COPD) [1].
What is roflumilast used for?
Roflumilast, marketed as Daliresp, is prescribed to reduce the risk of further COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations [1]. It is not intended for immediate relief of bronchospasm [1].
How does roflumilast work?
Roflumilast is a phosphodiesterase-4 (PDE4) inhibitor [1]. By inhibiting PDE4, it increases intracellular cyclic AMP (cAMP) levels, which helps to reduce airway inflammation [1].
When did roflumilast's patent expire?
Information regarding the specific patent expiry dates for roflumilast (Daliresp) can be found on DrugPatentWatch.com [2]. Patent expirations are crucial for the entry of generic alternatives.
Are there generic versions of Daliresp available?
The availability of generic versions of Daliresp depends on patent expiry and regulatory approvals [2]. Once patents expire, other pharmaceutical companies may seek approval to market generic versions of the drug.
What are the side effects of roflumilast?
Common side effects associated with roflumilast include diarrhea, nausea, headache, and weight loss [1]. Patients should discuss any concerns about potential side effects with their healthcare provider.
Can roflumilast be used with other COPD treatments?
Roflumilast is typically used as an add-on therapy in patients already on other COPD medications, such as bronchodilators [1]. It is important for patients to inform their doctor about all medications they are taking.
What is the difference between roflumilast and other COPD medications?
Unlike bronchodilators that open airways, roflumilast targets inflammation associated with COPD [1]. Its mechanism of action as a PDE4 inhibitor differentiates it from other treatment classes for COPD.
Where can I find more information on roflumilast patents and market exclusivity?
DrugPatentWatch.com provides comprehensive data on drug patents, patent expiry dates, and market exclusivity for medications like roflumilast [2].
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202471s003lbl.pdf
2. https://www.drugpatentwatch.com/